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In the last few decades, advances in molecular imaging technologies have had a major impact 
on many aspects of healthcare. In particular, radiohalogenated compounds have been used for 
non-invasive visualization of human anatomy, the diagnosis of disease and in drug 
development programs. As a consequence of these advances, a range of novel synthetic 
radiochemical methods have been reported that allow more effective and efficient 
radiohalogenation from a broader range of precursors. In developing new radiochemical 
methods, special requirements are required to optimize the incorporation of highly radioactive, 
short-lived, isotopically labelled reagents. This concept article highlights the key practical 
considerations and challenges required when utilizing the most commonly used radiohalogens 










Molecular imaging technologies such as positron emission tomography (PET) and single 
photon emission computed tomography (SPECT) in combination with radionuclide-labelled 
compounds have had a significant impact in the medical and life sciences.1 The development 
of novel imaging agents have resulted in a wide range of healthcare applications such as 
clinical diagnosis and prognosis for diseases associated with neurology, oncology and 
cardiology.1,2 Radionuclide based tracers have also been used in drug discovery programs and 
to monitor therapy. For example, 2-[18F]fluoro-2-deoxyglucose (FDG) (1) is used worldwide in 
healthcare facilities for the detection and diagnosis of human malignancies, such as lung, 
breast and colorectal cancers, and lymphoma and melanoma (Figure 1).3 The cocaine 
derivative, [123I]FP-CIT (ioflupane), is used as a radiopharmaceutical for the detection of the 
dopamine transporter and the subsequent clinical diagnosis of dementia disorders,4 such as 
Parkinson’s disease. 
 
Figure 1 Chemical structures of [18F]FDG (1) and [123I]FP-CIT (2). 
The continued growth and importance of PET and SPECT imaging has driven the need for 
new molecular tracers and chemical methods for the radiolabelling of precursor compounds.  
In terms of radiohalogenated imaging agents, [18F]-labelled compounds are most widely used 
in PET imaging, while [123I]- and [125I]-labelled compounds are commonly used for SPECT 
imaging and preclinical studies, respectively.1,2 There are many well documented advantages 
for the incorporation of fluorine atoms in bioactive compounds.5 In terms of PET imaging, 
fluorine-18 has many favorable nuclear properties, such as a relatively long half-life of 110 
minutes that allows for more complex radiosynthesis and longer in vivo studies. Fluorine-18 
also has a high percentage of + emission (97%) and a relatively low positron energy. A 
consequence of the low positron energy is that the distance traveled by the positron (positron 
range) before it undergoes annihilation by an electron is relatively small. This ultimately leads 
to higher resolution spatial images. In contrast, although the use of radioiodine and SPECT 
imaging generates lower resolution images, the longer half-life of iodine-123 (13.2 h), allows a 
wider range of radiosynthesis reactions and imaging studies.1 Furthermore, compounds can 
also be incorporated with [125I]iodide or [131I]iodide and used in preclinical development or 
radiotherapy applications, respectively.1a Isotopes of bromine (e.g. bromine-75 and -76) are 
positron emitting and so have been used for PET imaging.1a However, the production and 
isolation of these radionuclides is not trivial (e.g. isolation by dry distillation) and they possess 
non-ideal nuclear properties. For example, bromine-75 (half-life of 97 minutes) has high 
positron energy and a second-high energy gamma emission, both of which result in poor 
resolution for imaging. As a consequence, radionuclides of bromine are less commonly used 
for molecular imaging.  
With the growth and advances in PET and SPECT imaging, there have been significant efforts 
in developing new radiochemical methods for the synthesis of radiofluorinated and 
radioiodinated compounds.6-8 However, the translation of non-radioactive halogenation 
methods for use with radioactive reagents often requires further development. New 
radiohalogenation reactions entail significant re-optimization when handling highly 
radioactive, short-lived isotopically labelled reagents. This concept article describes the key 
challenges when developing radiohalogenation reactions for the preparation of 
radiopharmaceuticals or molecular imaging agents. 
 
2 Synthetic Challenges for Radiohalogenation 
As well as the safety issues when handling highly radioactive regents that are positron- or -
ray emitters (use of lead-shielded fumehoods or hot-cells), there are a number of general 
factors to consider when developing radiohalogenation methods. One of the key objectives 
is the preparation of radiolabelled products with high specific radioactivity.1 Achieving this 
aim allows radiotracers to be administered to humans in low enough doses that minimizes 
any toxic or pharmacological side-effects. This requires maximizing the short-lived 
radioisotope by late-stage introduction and fast reaction and purification times. In general, 
the reaction and purification timeframe should not exceed 2–3 times the half-life of the 
radionuclide. During most radiohalogenation reactions, the radiolabelled reagent is limiting, 
with an excess used of the substrate and other reagents. This has the combined effect of both 
driving the reaction of the radiolabelled reagent to completion and maximizing its use. The 
other major difference between non-radiohalogenation and radiohalogenation reactions is 
scale. As both PET and SPECT are highly sensitive techniques, radiotracers are administered 
in low amounts (<1–10 nmol).1a As a consequence of this and the safety issues with handling 
highly radioactive material, radiotracers are generally prepared on micromolar scale. Thus, 
following optimization of a halogenation reaction using typically milligram quantities of the 
precursor, translation to the sub-milligram radiolabelled version normally requires re-
optimization. This is generally done in combination with the changes described above, such 
as using the radiohalogen as the limiting reagent.  At this scale, the radiohalogenation 
reactions are monitored using (radio)-HPLC, where the production and purity of the 




Figure 2 Gold-catalyzed radio-iododeboronation reaction (0.6 mg scale reaction). Chromatogram shows an overlay of the radio-HPLC trace of 
reaction mixture (blue) and UV/Vis trace of non-radioactive product (black). 
2.1 Radiofluorination 
Radiofluorination reactions can be performed directly using nucleophilic [18F]fluoride or with 
electrophilic [18F]fluorine gas ([18F]F2) or fluorine-18 derived reagents.1,2 Fluorine-18 (half-life 
of 109.7 minutes) is most commonly produced using a cyclotron by proton irradiation of 18O-
enriched water.10 This produces the [18F]fluoride ion as a solution in the irradiated target 
water. As a consequence of this approach, the first stage of any radiofluorination reaction 
with [18F]fluoride is a drying step, as hydrated fluoride has significantly diminished 
nucleophilicity.11 This is typically done by adsorption of the [18F]fluoride ion onto an ion 
exchange resin.12 This also allows recovery of the expensive [18O]water. The [18F]fluoride ion 
is then eluted in a small volume of an aqueous base in the presence of a cryptand such as the 
aminopolyether K222 (Scheme 1) or as a tetraalkylammonium salt. Azeotropic evaporation 
with acetonitrile then provides a reagent that can be used for a wide-range of nucleophilic 
transformations. 
 
Scheme 1 Preparation of [18F]fluoride ion from cyclotron-irradiated [18O]water. 
The effort of achieving dehydrated [18F]fluoride ion has to be balanced with the time required 
to do this and completely dry fluoride may not always be necessary. For example, while a high 
degree of dryness is important for difficult nucleophilic aromatic substitution reactions, less 
rigorous drying can be used for less demanding nucleophilic aliphatic substitution reactions.13 
In recent years, alternative methods to azeotropic drying, such as eluting [18F]fluoride from 
modified solid-phase extraction (SPE) cartridges14 or from ion-exchange resins using organic 
bases have provided dry fluoride ion with high recovery of activity.15 It should also be noted 
that the [18F]fluoride ion can “stick” to reaction vessel walls. This can be minimized with the 
use of pyrex vessels, rather than those composed of glassy carbon or platinum.12 When all of 
these conditions are met, [18F]fluoride/K222 solutions can then be used for radiolabeling using 
typical organic reactions. In the standard examples shown in scheme 2, nucleophilic aliphatic 
fluorination for the preparation of the tumor proliferation imaging agent 3’-deoxy-3’-
[18F]fluorothymidine ([18F]FLT) (3)16 and nucleophilic aromatic fluorination generating the 
nicotinic acetylcholine receptor imaging agent [18F]norchlorofluoroepibatidine (4),17 the 
reactions with [18F]fluoride/K222 solutions were performed at high temperatures, resulting in 
short reaction times. The work up and purification of these reactions are also typical, with a 
dilution step, initial purification by passing the reaction mixture through a C-18 cartridge, 
followed by a final purification by HPLC. 
 
Scheme 2 Radiosynthesis of [18F]FLT (3) and [18F]norchlorofluoroepibatidine (4). DMT: 4,4’-dimethoxytriphenylmethyl; RCY: radiochemical yield. 
Electrophilic radiofluorination can be achieved using highly reactive [18F]fluorine gas.  [18F]F2 
is produced by targeting [18O]oxygen.6a However, the specific activity of the [18F]F2 is 
compromised by the use of [19F]F2 as a carrier gas and the enriched [18F]F2 requires cryogenic 
trapping. While [18F]F2 is widely used for radiofluorination reactions and the preparation of 
less reactive electrophilic radiofluorinating reagents, such as acetyl [18F]hypofluorite, 
[18F]XeF2 or N-[18F]fluorosulfonamide, [18F]fluoride is often used as a more active, indirect 
source of electrophilic fluorine-18. An example of this approach has been described by Solin, 
Gouverneur and co-workers for the preparation of [18F]selectfluor (bis)triflate (5) (Scheme 
3).18 This method generated [18F]F2 from [18F]fluoride with high specific activity in an electrical 
discharge chamber using [18F]fluoromethane as an intermediate. The resulting [18F]selectfluor 
reagent was used for a range of reactions, including aryl fluorodeboronation and the 
radiosynthesis of 6-[18F]fluoro-L-DOPA (6), a PET imaging agent for the dopaminergic 
pathways.19 Although involving several steps, electrophilic approaches such as this allow the 
preparation of radiofluorinated compounds with high specific activity via a [18F]F2 source. 
While such advances have expanded methods for electrophilic fluorination in research, the 
specialized equipment needed (e.g. discharge chamber) has restricted widespread use in 
nuclear medicine facilities. As a consequence, nucleophilic fluorination or the use of [18F]F2 
are still the most common approaches for the production of clinically used radiofluorinated 
tracers.20 
  
Scheme 3 Radiosynthesis of high activity [18F]F2 and [18F]selectfluor 5 and application in the preparation of 6-[18F]fluoro-L-DOPA (6). 
2.2 Radioiodination 
The most commonly used radioisotopes of iodine are 123, 125 and 131.1,7 Iodine-123 which 
is a gamma emitter and has a half-life of 13.2 hours is the most used non-metal radionuclide 
for SPECT imaging. Iodine-125 has a half-life of 59.4 days and is used in preclinical research, 
such as radioimmunoassay techniques, binding studies and autoradiography, while the high 
energy iodine-131 radionuclide (half-life of 8.02 days) is mainly used in radiotherapy. Iodine-
124, which is a positron-emitting radionuclide, with a half-life of 4.2 days has been less 
commonly used due to its complex radioactive decay process. However, more recently, this 
radionuclide is finding greater application for PET imaging.21 As a consequence of the 
significantly longer half-lives, local nuclear facilities are not necessary. The radioisotopes of 
iodine can be made in central commercial facilities and transported to where they are 
required. 
 All radioiodine isotopes are produced in iodide form, commonly as sodium iodide in 
solutions of sodium hydroxide (0.01–0.1 M). In a similar manner to aqueous solutions of 
[18F]fluoride, enriched iodide requires drying before most applications, however, the time 
required to do this is less of an issue. Traditional nucleophilic reactions of iodide can be used 
directly to incorporate radioiodine into organic compounds.1,7 Alternatively, iodide can be 
oxidized to iodine or iodine monochloride and subjected to electrophilic reactions. For the 
preparation of many aryl-based SPECT tracers this can be done by direct electrophilic 
aromatic substitution or by use of a leaving group, such as in iodo-destannylation reactions 
(Scheme 4).22,23 In common with radiofluorination reactions, minimal work up is involved with 
these processes, typically requiring dilution and purification by prep-HPLC. Validation of the 




Scheme 4 Examples of electrophilic radioiodination. 
These types of transformations are commonly used in healthcare facilities for the 
preparation of iodine-123 SPECT imaging agents, mainly as they are fast and produce the 
tracer in high specific activity.1,7 However, strong oxidizing agents such as chloramine-T, 
peracetic acid and iodogen are not compatible with a wide range of organic compounds and 
organotin precursors are highly toxic and can be unstable.  
For these reasons, in recent years, a wide range of radioiodination methods, mainly 
involving transition metal mediated processes have been developed.8 Like the more 
traditional transformations, these processes have required further development on 
translation from the non-radioactive version. A good example of this is a nickel(0)-catalyzed 
halogen exchange process reported by Sutherland and co-workers.24 A general iodination 
process of aryl bromides was developed using in situ generation of nickel(0) and an excess of 
sodium iodide (Scheme 5). In a radioactive version, which used radioiodide as the limiting 
reagent, higher loadings of the nickel(II) bromide pre-catalyst were required for reaction.8a 
However, the increased concentration of bromide ion interfered with the equilibrium of 
halogen exchange, resulting in moderate conversion to the radioiodine products (<29%). As 
a consequence, the nickel(0)-mediated radioiodination of aryl bromides had to be re-
developed using a non-bromide source of nickel(0). The use of Ni(cod)2 was found to be 
optimal under the conditions for radioiodination and was compatible with incorporation of 
either iodine-123 or -125 (Scheme 5). While this required 40 mol% of the catalyst, on typical 
micromolar scale used for radioiodination reactions, this equates to a relatively small amount 
of the nickel complex (<0.5 mg). 
 
Scheme 5 Non-radioactive versus radioactive nickel(0)-mediated iodination for the preparation of [125I]iniparib.  
 
 
3 Conclusions and Future Outlook 
In summary, typical fluorine and iodine-based reactions can be performed for 
radiohalogenation of organic compounds. However, the highly radioactive material and short 
half-lives require the radiohalogenation step to be fast, easy to purify and usually the last step 
in the synthetic route. Translation from a previously developed non-radioactive method 
generally requires re-optimization, particularly as the radiohalogen source is normally the 
limiting reagent during these transformations. Due to these changes of scale and 
stoichiometry, some radiohalogenation reactions have been developed and optimized 
directly, without prior investigation with a non-radioactive method.1,6,7 For general 
application in clinical and nuclear medical facilities, methods should be operationally simple 
and avoid highly toxic precursors and reagents. 
 As with other areas of organic synthesis, radiochemical methods for halogenation continue 
to embrace new technologies that facilitate fast reactions and allow simple purification. For 
example, reactions have been accelerated using microwave irradiation,25 flow- and micro-
reactors,26 while purification has been simplified using solid-supported substrates or 
reagents.1,2,27 It should also be noted that while the development of many radiohalogenation 
methods is still performed manually, commercial production of tracers used in medical 
imaging is done using automatic synthesizer modules in which components of the reaction 
are supplied by cassettes, with minimal contact with the human operator. New 
radiohalogenation chemistry continues to be discovered. A notable example is from the 
O’Hagan laboratory where a biocatalytic radiofluorination using the fluorinase enzyme has 
allowed the preparation of 5’-[18F]fluoro-5’-deoxyadenosine and other biomolecules in high 
radiochemical yield.28 Methods that allow the incorporation of other radiohalogens are also 
being reported. These include the preparation of small molecules bearing astatine-211, an -
particle emitting radionuclide that has potential for targeted radiotherapy.1a,29 All of these 
new technologies continue to expand the limits of radiohalogenation reactions, producing 
labelled compounds with high specific activity. This of course underpins the subsequent 
development of the highly important applications of these compounds in medical imaging of 
disease and as radiopharmaceuticals.  
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